Results 11 to 20 of about 382,920 (355)

Multiple myeloma

Nature Reviews Disease Primers
Multiple myeloma (MM) is a haematological lymphoid malignancy involving tumoural plasma cells and is usually characterized by the presence of a monoclonal immunoglobulin protein. MM is the second most common haematological malignancy, with an increasing global incidence.
Mohammad Ahmad Amin
openalex   +4 more sources

Multiple myeloma

The Lancet, 2021
Multiple myeloma is the second most common haematological malignancy in high-income countries, and typically starts as asymptomatic precursor conditions-either monoclonal gammopathy of undetermined significance or smouldering multiple myeloma-in which ...
Juan Carlos Santizo Castillo
openalex   +2 more sources

Multiple Myeloma [PDF]

New England Journal of Medicine, 2004
AbstractMultiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. In this paper, we present a historically focused review of the disease, from the description of the first case in 1844 to the present.
Robert A, Kyle, S Vincent, Rajkumar
  +13 more sources

Multiple Myeloma [PDF]

Journal of the National Comprehensive Cancer Network, 2011
Multiple myeloma (MM) is a B cell neoplasm of the bone marrow with a complex array of clinical manifestations including anemia, bone lesions, hypercalcemia, renal dysfunction, and compromised immune function. It accounts for 10%–15% of all hematologic malignancies, and 20% of deaths related to cancers of the blood and bone marrow.
Kenneth C, Anderson, Melissa, Alsina, William, Bensinger, J Sybil, Biermann, Asher, Chanan-Khan, Adam D, Cohen, Steven, Devine, Benjamin, Djulbegovic, Edward A, Faber, Cristina, Gasparetto, Carol Ann, Huff, Adetola, Kassim, Bruno C, Medeiros, Ruby, Meredith, Noopur, Raje, Jeffrey, Schriber, Seema, Singhal, George, Somlo, Keith, Stockerl-Goldstein, Steven P, Treon, Guido, Tricot, Donna M, Weber, Joachim, Yahalom, Furhan, Yunus   +23 more
  +8 more sources

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

New England Journal of Medicine, 2021
BACKGROUND Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and ...
N. Munshi, L. Anderson, N. Shah, D. Madduri, J. Berdeja, S. Lonial, N. Raje, Yi Lin, D. Siegel, A. Oriol, P. Moreau, I. Yakoub-Agha, M. Delforge, M. Cavo, H. Einsele, H. Goldschmidt, K. Weisel, A. Rambaldi, D. Reece, F. Petrocca, M. Massaro, Jamie N. Connarn, S. Kaiser, P. Patel, Liping Huang, T. Campbell, K. Hege, J. San-Miguel   +27 more
semanticscholar   +1 more source

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

New England Journal of Medicine, 2023
BACKGROUND Survival is poor among patients with triple-class-exposed relapsed and refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, previously led to deep ...
P. Rodríguez-Otero, S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo, A. Nooka, S. Manier, N. Callander, L. Costa, R. Vij, N. Bahlis, P. Moreau, S. Solomon, M. Delforge, J. Berdeja, A. Truppel-Hartmann, Zhihong Yang, L. Favre‐Kontula, Fan Wu, J. Piasecki, M. Cook, S. Giralt   +21 more
semanticscholar   +1 more source

Teclistamab in Relapsed or Refractory Multiple Myeloma

New England Journal of Medicine, 2022
BACKGROUND Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells.
P. Moreau, A. Garfall, N. V. D. van de Donk, H. Nahi, J. San-Miguel, A. Oriol, A. Nooka, T. Martin, L. Rosiñol, A. Chari, L. Karlin, L. Benboubker, M. Mateos, N. Bahlis, R. Popat, B. Besemer, J. Martínez-López, S. Sidana, M. Delforge, L. Pei, D. Trancucci, R. Verona, S. Girgis, S. X. W. Lin, Y. Olyslager, M. Jaffe, C. Uhlar, T. Stephenson, R. Van Rampelbergh, A. Banerjee, J. Goldberg, R. Kobos, A. Krishnan, S. Usmani   +33 more
semanticscholar   +1 more source

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

American journal of hematology/oncology, 2022
Multiple myeloma accounts for approximately 10% of hematologic malignancies.
S. Rajkumar
semanticscholar   +1 more source

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

New England Journal of Medicine, 2023
BACKGROUND Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of ...
P. Sonneveld, M. Dimopoulos, M. Boccadoro, H. Quach, P. J. Ho, M. Beksaç, C. Hulin, Elisabetta Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, F. Gay, R. Mina, I. Nijhof, Niels W C J van de Donk, E. Katodritou, Fredrik H. Schjesvold, Anna Sureda Balari, L. Rosiñol, Michel Delforge, W. Roeloffzen, T. Silzle, A. Vangsted, H. Einsele, A. Spencer, Roman Hájek, Artur Jurczyszyn, Sarah Lonergan, T. Ahmadi, Yanfang Liu, Jianping Wang, D. Vieyra, Emilie M.J. van Brummelen, V. Vanquickelberghe, A. Sitthi-Amorn, Carla J. de Boer, R. Carson, P. Rodríguez-Otero, J. Bladé, P. Moreau   +42 more
semanticscholar   +1 more source

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma

Cells, 2022
Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients.
Megan Johnstone, Delaney Vinaixa, Marcello Turi, Eugenio Morelli, Kenneth Carl Anderson, Annamaria Gulla   +5 more
doaj   +1 more source